Best Pharmaceutical Products Wholesaler Cary Near Me

4worldlovers: We know what transplant means to patients, and we’re leading innovation to improve their experience

For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey. Our focus is developing new therapies and programs to help transplant healthcare providers and the patients they treat.

As part of a global network, Veloxis is reaching further and growing faster

As an Asahi Kasei company, we are able to expand our presence as a partner in care and innovation in medicine. The support and structured framework we have as part of Asahi Kasei enables us to be who we are as a company: agile, efficient, and responsive.

“Veloxis’s Human Resources Department prides itself in providing an exceptional workplace environment for all employees. We strive to maintain a dynamic and innovative workplace that embraces diversity and encourages professional development. Our employees are our top priority!”

Keep up with our headlines to see what we’ve been working on

Veloxis Pharmaceuticals Partners with Donate Life NC on Gift of Life Gala

Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, is pleased to announce its support of Donate Life North Carolina as the premier sponsor of the 2023 Gift of Life Gala: heART of the Matter on Thursday, April 20th at the Prestonwood Country Club in Cary, N.C.

Veloxis Pharmaceuticals and Lyfebulb Announce Winners of the 2022 Innovation Challenge in Organ Transplantation

Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, and Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, are pleased to announce that Isabel Portero, M.D., Ph.D., founder and CEO at Biohope Scientific Solutions, and Chet Bennett, founder at the C. Alan Foundation, have been selected as the winners of the 2022 Lyfebulb – Veloxis Innovation Challenge.

C-Path's Transplant Therapeutics Consortium receives EMA Draft Qualification Opinion for the iBox Scoring System

Critical Path Institute (C-Path) announced October 13, 2022 that its Transplant Therapeutic Consortium (TTC), of which Veloxis Pharmaceuticals is a member, received a draft qualification opinion for the iBox Scoring System through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development.